Mei Zhu

Summary

Country: China

Publications

  1. ncbi request reprint [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients]
    Mei Zhu
    Clinical Immunology Research Center, Jing an Qu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 13:534-6. 2005
  2. ncbi request reprint [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B]
    Guang Bi Yao
    Clinical Immunology Research Center, Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Zhonghua Nei Ke Za Zhi 45:891-5. 2006
  3. doi request reprint A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China
    Guang Bi Yao
    Beijing Ditan Hospital, Beijing, China
    J Dig Dis 10:131-7. 2009

Detail Information

Publications3

  1. ncbi request reprint [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients]
    Mei Zhu
    Clinical Immunology Research Center, Jing an Qu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 13:534-6. 2005
    ..To investigate the factors which may affect the rate of HBeAg seroconversion and its durability after long-term lamivudine therapy in chronic hepatitis B patients...
  2. ncbi request reprint [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B]
    Guang Bi Yao
    Clinical Immunology Research Center, Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Zhonghua Nei Ke Za Zhi 45:891-5. 2006
    ..This study was to evaluate the antiviral efficacy and safety in nucleoside naive Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV) or lamivadine (LVD)...
  3. doi request reprint A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China
    Guang Bi Yao
    Beijing Ditan Hospital, Beijing, China
    J Dig Dis 10:131-7. 2009
    ..To evaluate the long-term efficacy and safety of lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepatitis B virus (HBV)...